Table 2.
Cancers associated with SKP2 deregulation
| Human cancer | Correlation with poor prognosis | Correlation with low p27 levels | Refs |
|---|---|---|---|
| Biliary tract cancer | Yes | No | 143 |
| Breast cancer* | Yes | Yes | 32, 42, 144–145 |
| Cervical cancer | Yes | No | 146 |
| Colon cancer* | Yes | Yes | 39, 43, 147–148 |
| Endometrial cancer | Yes | ND | 149–150 |
| Gastric cancer* | Yes | Yes | 45, 151–152 |
| Glioma/glioblastoma‡ | Yes | Yes | 153–154 |
| Kaposi sarcoma | Yes | No | 155 |
| Lung cancer (NSLC) *‡ | Yes | Yes | 156–158 |
| Lung cancer (SLC)* | Yes | Yes | 157–159 |
| Lymphoma and leukaemia | Yes | No | 40 |
| Multiple myeloma | Yes | Yes | 160–161 |
| Melanoma | Yes | Yes | 162–165 |
| Oral cancers | Yes | Yes | 147, 166–169 |
| Ovarian cancer | Yes | Yes | 170–171 |
| Prostate cancer | Yes | Yes | 34, 172–173 |
*
CKS1 (CDK subunit 1) also upregulated.
‡
Gene amplification. ND, not determined; NSLC, non-small-cell lung cancer; SKP2, S-phase kinase-associated protein 2; SLC, small-cell lung cancer.